Northern Trust’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-355,860
| Closed | -$7.72M | – | 4315 |
|
|
2017
Q2 | $7.72M | Buy |
355,860
+14,765
| +4% | +$268K | ﹤0.01% | 2329 |
|
|
2017
Q1 | $4.79M | Sell |
341,095
-8,588
| -2% | -$141K | ﹤0.01% | 2578 |
|
|
2016
Q4 | $6.56M | Buy |
349,683
+657
| +0.2% | +$11.2K | ﹤0.01% | 2366 |
|
|
2016
Q3 | $5.76M | Sell |
349,026
-616
| -0.2% | -$9.13K | ﹤0.01% | 2432 |
|
|
2016
Q2 | $4.7M | Sell |
349,642
-3,944
| -1% | -$57.5K | ﹤0.01% | 2512 |
|
|
2016
Q1 | $5.46M | Sell |
353,586
-100,889
| -22% | -$1.58M | ﹤0.01% | 2359 |
|
|
2015
Q4 | $9.02M | Buy |
454,475
+11,267
| +3% | +$214K | ﹤0.01% | 2088 |
|
|
2015
Q3 | $7.72M | Buy |
443,208
+54,888
| +14% | +$1.12M | ﹤0.01% | 2164 |
|
|
2015
Q2 | $7.85M | Buy |
388,320
+25,692
| +7% | +$496K | ﹤0.01% | 2221 |
|
|
2015
Q1 | $6.38M | Buy |
362,628
+67,864
| +23% | +$1.16M | ﹤0.01% | 2353 |
|
|
2014
Q4 | $4.8M | Buy |
294,764
+1,964
| +0.7% | +$36K | ﹤0.01% | 2530 |
|
|
2014
Q3 | $6.46M | Buy |
292,800
+1,465
| +0.5% | +$30K | ﹤0.01% | 2344 |
|
|
2014
Q2 | $5.86M | Sell |
291,335
-25,884
| -8% | -$438K | ﹤0.01% | 2409 |
|
|
2014
Q1 | $5.9M | Sell |
317,219
-20,434
| -6% | -$281K | ﹤0.01% | 2451 |
|
|
2013
Q4 | $3.4M | Buy |
337,653
+321
| +0.1% | +$3.88K | ﹤0.01% | 2816 |
|
|
2013
Q3 | $4.35M | Buy |
337,332
+167,456
| +99% | +$2.06M | ﹤0.01% | 2599 |
|
|
2013
Q2 | $2.02M | Buy |
+169,876
| New | +$1.84M | ﹤0.01% | 2982 |
|
Other funds holding AMRI
Northern Trust's AMRI Position: Q3 2017 in Review
Northern Trust sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 355,860 shares — an estimated $7.72M sold.
Northern Trust first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $9.02M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Northern Trust reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Northern Trust sold 355,860 Albany Molecular Research Inc shares in Q3 2017, an estimated $7.72M.
- Northern Trust first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Northern Trust's Albany Molecular Research Inc position peaked at $9.02M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Northern Trust's 13F filing for Q3 2017, filed 13 Nov 2017.